Sjögren's drug shows promise in safety extension trial

NCT ID NCT06203457

Completed Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at the long-term safety of efgartigimod in 24 adults with primary Sjögren's syndrome who had already completed a prior trial. Efgartigimod works by lowering certain antibodies that may drive the disease. The main goal was to track side effects over 48 weeks, with a secondary look at whether symptoms improved.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: efgartigimod
What this could lead to: If it works, this could point toward a treatment that reduces disease activity and symptoms in Sjögren's syndrome.
What could go wrong: This is a small, early-phase safety extension study, not designed to prove effectiveness. The drug may not improve symptoms and carries risks like infections due to lowered antibody levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sjogren syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY SJÖGREN'S SYNDROME

Contacts and locations

Locations

Centrum Medyczne Plejady

Krakow, 30 363, Poland
Centrum Medyczne Pratia Poznan

Skorzewo, 60 185, Poland
Clinical Research Center Spółka z ograniczoną odpowiedzialnością Medic-R Sp.k.

Poznan, 60-848, Poland
Debreceni Egyetem

Debrecen, 4032, Hungary
FutureMeds sp zoo

Wroclaw, 50 088, Poland
Klinika Reuma Park Sp zoo Sp K

Warsaw, 02 665, Poland
MCBK SC

Grodzisk Mazowiecki, 05 825, Poland
MICS Centrum Medyczne Warszawa

Warsaw, 00 874, Poland
Narodowy Instytut Geriatrii

Warsaw, 02637, Poland
Universitair Ziekenhuis Gent

Ghent, 9000, Belgium
Vita Verum Medical Egeszsegugyi Szolgaltato Bt.

Székesfehérvár, 8000, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.